Jeong Heo, Takuji Okusaka, Jung-Hwan Yoon, Bruno Sangro, Stephen Lam Chan, Joseph P. Erinjeri, Marco Matos, Thomas Decaens, Eric Xueyu Chen, Muhammad S. Beg, Ana Maria Matilla, Le Thi Tuyet Phuong, Rebecca Griffin, Stephanie I. Udoye, Sandra Indiviglio, Masatoshi Kudo. "Outcomes by transarterial chemoembolization (TACE) modality from participants (pts) with embolization-eligible hepatocellular carcinoma (HCC) treated with durvalumab (D) + bevacizumab (B) + TACE and placebos (PBO) + TACE: EMERALD-1 subgroup analysis.." Journal of Clinical Oncology, 2025. doi:10.1200/jco.2025.43.4_suppl.575